Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Reprogram-Diabetes

Financiado

Cerrado

In vivo drug discovery for cellular reprogramming to cells towards a future...

In vivo drug discovery for cellular reprogramming to cells towards a future regenerative therapy for diabetes For almost a century we have been able to control diabetes with insulin injections, yet we still have no cure for this prevalent disease. One possible way to cure diabetes is by increasing the number of insulin-producing β-cells i... ver más

30/09/2024

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UPPSALA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-09-30

ERC-2017-COG: ERC Consolidator Grant

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

200.00K€ | Lider

INGENIERIA ASTURIANA TERMOEL...

333.54K€ | Participante

1.80M€ | Participante

Proyectos interesantes

ZF-BrainReg

Medical Technol...

Data Science

3M€ Cerrado

BLOODY SIGNALS

Medical Technol...

Data Science

100K€ Cerrado

PTQ-12-05352

Medical Technol...

Data Science

61K€ Cerrado

HEART_STATES

Medical Technol...

Data Science

2M€ Cerrado

SCSC

Medical Technol...

Data Science

192K€ Cerrado

ZF_Blood

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 78 meses Fecha Inicio: 2018-03-14
Fecha Fin: 2024-09-30

Líder del proyecto

UPPSALA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto For almost a century we have been able to control diabetes with insulin injections, yet we still have no cure for this prevalent disease. One possible way to cure diabetes is by increasing the number of insulin-producing β-cells in the pancreas. Here, I propose to uncover factors and mechanisms that can increase β-cell numbers through cellular reprogramming. To do so, we will use two complementary discovery approaches—and transition between zebrafish, mouse and human analyses—to perform functional studies with high translational value. First, we will use a novel drug discovery approach in transgenic zebrafish to identify and characterize small molecules that can promote the reprogramming of various pancreatic cell types to β-cells. Second, we will use single-cell RNA-sequencing to identify genetic signatures of cellular reprogramming to β-cells in humans, and then dissect the function of the identified genes by overexpressing or mutating them in transgenic zebrafish. We will also use lineage-tracing to determine the number and origin of the β-cells the small molecules and genes induce. Once we identify promising hits in zebrafish, we will treat diabetic mice with small molecules or secreted proteins (targeting the signalling pathways regulated by the hits) and evaluate their effects on glucose control and β-cell mass. We will also test their effects on cellular reprogramming in mice, as indicated by changes in the relative proportion of each hormonal cell type, in the generation of bihormonal cells (insulin+ glucagon+ or insulin+ somatostatin+), and in the number of lineage-traced β-cells. Further, we will determine whether these small molecules or secreted proteins induce reprogramming to β-cells in human islets. By coupling whole-organism screens with mechanistic and translational studies, we will identify factors and pathways that can enhance cellular reprogramming to β-cells and could thus form the basis of a cure for diabetes.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores